跳至主要内容
临床试验/NCT00378625
NCT00378625已完成3 期

Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia

Centro Internacional de Entrenamiento e Investigaciones Médicas2 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2000年4月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
360
试验地点
2
主要终点
treatment failures

研究概览

简要总结

The primary goal of this study is to quantify the benefit of adding artesunate to amodiaquine in treating patients with uncomplicated P. falciparum malaria, in a low transmission area in Colombia. The benefit will be assessed in terms of:

  • Efficacy
  • Tolerability
  • Time of fever clearance
  • Time of parasite clearance
  • Proportion of gametocyte carriers

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
盲法
Double

入排标准

年龄范围
1 Year 至 65 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • pure P. falciparum infection
  • parasitaemia >500 and <50,000 asexual parasites/μL (subsequently the lower limit was modified to >250 asexual parasites/μL)
  • age between 1 and 65 years old
  • availability to return for follow-up

排除标准

  • history of allergy to the study drugs
  • history of taken complete treatment with an antimalarial drug in the previous 72 hours or sulphas, clindamycin or tetracycline in the previous week
  • have a medical history of untreated hypertension or chronic heart, kidney or liver disease
  • present any danger signs of severe malaria.

结局指标

主要结局

treatment failures

adverse events

gametocyte carriage

次要结局

未报告次要终点

研究者

发起方
Centro Internacional de Entrenamiento e Investigaciones Médicas
申办方类型
Other

研究点 (2)

Loading locations...

相似试验